Nephropathy Clinical Trials in Shanghai
13 recruitingShanghai, China
Showing 1–13 of 13 trials
Recruiting
Phase 2
Chinese Adults With Kidney Disease
Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 1
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd52 enrolled6 locationsNCT05668403
Recruiting
Phase 2Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled86 locationsNCT07204275
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 2
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled8 locationsNCT07146906
Recruiting
Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Early Phase 1
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital36 enrolled1 locationNCT07241468
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Lupus Nephritis (LN)Membranous Nephropathy
Shanghai Henlius Biotech24 enrolled17 locationsNCT07038382
Recruiting
Early Phase 1
An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy
Nephropathy
Changhai Hospital36 enrolled1 locationNCT06469190
Recruiting
TESTING -ON Post-Trial ObservatioNal Cohort Study
Kidney DiseasesIgA NephropathyGlomerulonephritis+1 more
The George Institute366 enrolled58 locationsNCT05434325
Recruiting
Not Applicable
Efficacy and Safety of Telitacicept in IgAN
GlucocorticoidKidney DiseasesIgA Nephropathy (IgAN)+1 more
Ruijin Hospital118 enrolled1 locationNCT06654596